Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329784 | 0.79 | KMT2A (0.62) | KMT2AAKR1B1ADRA2AMEN1LMNA | |
| SCHEMBL8744800 | 0.77 | AKR1B1 (0.53) | KMT2AAKR1B1POLBALDH1A1HPGD | |
| SCHEMBL8744794 | 0.77 | AKR1B1 (0.53) | KMT2AAKR1B1POLBALDH1A1HPGD | |
| SCHEMBL9527443 | 0.75 | KMT2A (0.61) | KMT2AAKR1B1HPGDADRA2AMEN1 | |
| SCHEMBL8744811 | 0.75 | SDCBP (0.51) | KMT2AAKR1B1POLBALDH1A1HPGD | |
| SCHEMBL8744816 | 0.75 | SDCBP (0.51) | KMT2AAKR1B1POLBALDH1A1HPGD | |
| SCHEMBL13485815 | 0.73 | KMT2A (0.62) | KMT2AAKR1B1ADRA2AMEN1LMNA | |
| SCHEMBL23620100 | 0.73 | ALDH1A1 (0.58) | KMT2AAKR1B1POLBALDH1A1HPGD | |
| SCHEMBL8744785 | 0.73 | GRN (0.56) | KMT2AAKR1B1ALDH1A1SLC22A12LMNA | |
| SCHEMBL8744789 | 0.73 | GRN (0.56) | KMT2AAKR1B1ALDH1A1SLC22A12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449575-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA, INC. (BE) | 2008-11-11 | — | — | US | disclosed |
| US-20060189614-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PAUL A | 2006-08-24 | — | — | US | disclosed |
| US-20060049177-A1 | Induction heating cooker | LG ELECTRONICS INC. | 2006-03-09 | — | — | US | disclosed |
| US-6962916-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-08 | — | — | US | disclosed |
| US-6858609-B2 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-22 | — | — | US | disclosed |
| EP-0834507-B1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. | 2003-10-23 | — | — | US | disclosed |
| US-20020147181-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PAUL A J (BE) | 2002-10-10 | — | — | US | disclosed |
| US-6380194-B1 | FOR TREATMENT OF SUBJECTS SUFFERING FROM HIV INFECTION | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-30 | — | — | US | disclosed |
| EP-0834507-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | CCR1, CCR6, CCR5 | KMT2A 3442/4885AKR1B1 256/4885POLB 1996/4885 |
| US-20020147181-A1 | Substituted diamino-1,3,5-triazine derivatives | CCR1, CCR6, CCR5 | KMT2A 3284/4885AKR1B1 262/4885POLB 1803/4885 |
| US-20060189614-A1 | Substituted diamino-1,3,5-triazine derivatives | C5, ADORA1, C1S | KMT2A 3914/4885AKR1B1 104/4885POLB 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.